Supporting Information

Personalized, Disease-Specific Protein Corona Influences the Therapeutic Impact of Graphene Oxide

Mohammad Javad Hajipour [a,b,c] , Jamshid Raheb[a*], Omid Akhavan[d], Sareh Arjmand[e], Omid Mashinchian[c], Masoud Rahman[f], Mohammad Abdolahad[g,h], Vahid Serpooshan[i*], Sophie Laurent[j], and Morteza Mahmoudi[c,i,k *]

[a]Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.

[b]The Persian Gulf Marine Biotechnology Research Center, Bushehr University of Medical Sciences, Bushehr, Iran.

[c]Department of Nanotechnology and Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

[d]Department of Physics, Sharif University of Technology, P.O. Box 11155-9161, Tehran, Iran.

[e]Department of Clinical Biochemistry, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran.

[f]Department of Chemical Engineering and Materials Science, University of California Davis, Davis, CA 95616, USA

[g]Nano Electronic Center of Excellence,Thin Film and Nanoelectronic Lab,School of Electrical and Computer Eng, University of Tehran,Tehran, Iran, P.O. Box 14395/515,Tehran,Iran

[h]Nano Electronic Center of Excellence, Nano Bio Electronic Devices Lab, School of Electrical and Computer Eng,University of Tehran,Tehran, Iran, P.O. Box 14395/515,Tehran,Iran

[i]Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, United States.

[j]Department of General, Organic and Biomedical Chemistry, NMR and Molecular Imaging Laboratory, University of Mons, 19 Avenue Maistriau, B-7000 Mons, Belgium.

[k]Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, United States.

*Address correspondence to: (JR) jamshid@nigeb.ac.ir, (VS) vserp1@stanford.edu, (MM) Mahmoudi@stanford.edu



Figure S1. AFM images of hard corona coated CCGO sheets (5% plasma) obtained from diabetic patient (top panels) and their correspondence height profiles distribution (bottom panel).



Figure S2. AFM images of hard corona coated CCGO sheets (5% plasma) obtained from hypofibrinogenemia patient (top panels) and their correspondence height profiles distribution (bottom panel).



Figure S-3 A). Morphological sates of MCF-7 cells after incubation (24 h) with corona coated CCGO obtained from healthy subjects (P 5% and P50%).



Figure S-3 B). Morphological sates of MCF-7 cells after incubation (24 h) with corona coated CCGO obtained from pregnancy subjects (P 5% and P50%).



Figure S-3 C). Morphological sates of MCF-7 cells after incubation (24 h) with corona coated CCGO obtained from diabetic patients (P 5% and P50%).



Figure S-3 D). Morphological sates of MCF-7 cells after incubation (24 h) with corona coated CCGO obtained from hypercholesterolemia patients (P 5% and P50%).



Figure S-3 E). Morphological sates of MCF-7 cells after incubation (24 h) with corona coated CCGO obtained from rheumatism patients (P 5% and P50%).



Figure S-3 F). Morphological sates of MCF-7 cells after incubation (24 h) with corona coated CCGO obtained from thalassemia minor patients (P 5% and P50%).



Figure S-3 G). Morphological sates of MCF-7 cells after incubation (24 h) with corona coated CCGO obtained from thalassemia major patients (P 5% and P50%).



Figure S-3 H). Morphological sates of MCF-7 cells after incubation (24 h) with corona coated CCGO obtained from fauvism patients (P 5% and P50%).



Figure S-3 I). Morphological sates of MCF-7 cells after incubation (24 h) with corona coated CCGO obtained from blood cancer patients (P 5% and P50%).



Figure S3 J). Morphological sates of MCF-7 cells after incubation (24 h) with corona coated CCGO obtained from hypofibrinogenemia patients (P 5% and P50%).

MCF-7 cell-CONTROL (Nontreated)



Figure S3 K). Morphological sates of control MCF-7 cells.



Figure S4 A). Morphological sates of MDA-MB-231 cells after incubation (24 h) with corona coated CCGO obtained from healthy subjects (P 5% and P50%).



Figure S4 B). Morphological sates of MDA-MB-231 cells after incubation (24 h) with corona coated CCGO obtained from pregnancy subjects (P 5% and P50%).

Diabetes 5%, MDA-MB 231



Diabetes 50%, MDA-MB 231



Figure S4 C). Morphological sates of MDA-MB-231 cells after incubation (24 h) with corona coated CCGO obtained from diabetic patients (P 5% and P50%).



Figure S4 D). Morphological sates of MDA-MB-231 cells after incubation (24 h) with corona coated CCGO obtained from hypercholesterolemia patients (P 5% and P50%).



Figure S4 E). Morphological sates of MDA-MB-231 cells after incubation (24 h) with corona coated CCGO obtained from rheumatism patients (P 5% and P50%).



Figure S4 F). Morphological sates of MDA-MB-231 cells after incubation (24 h) with corona coated CCGO obtained from thalassemia minor patients (P 5% and P50%).



Figure S4 G). Morphological sates of MDA-MB-231 cells after incubation (24 h) with corona coated CCGO obtained from thalassemia major patients (P 5% and P50%).



Figure S4 H). Morphological sates of MDA-MB-231 cells after incubation (24 h) with corona coated CCGO obtained from fauvism patients (P 5% and P50%).



Figure S4 I). Morphological sates of MDA-MB-231 cells after incubation (24 h) with corona coated CCGO obtained from blood cancer patients (P 5% and P50%).



Figure S4 J). Morphological sates of MDA-MB-231 cells after incubation (24 h) with corona coated CCGO obtained from hypofibrinogenemia patients (P 5% and P50%).

MDA-MB 231 Control (Nontreated)



Figure S4 K). Morphological sates of control MDA-MB-231 cells.